tissue microarray device minicore (Alphelys Inc)
90
Structured Review
Alphelys Inc
tissue microarray device minicore
Tissue Microarray Device Minicore, supplied by Alphelys Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+microarray+device+minicore/tissue+arrayer+minicore/10__1097_slash_pai__0000000000001208-50-3-7
Average 90 stars, based on 1 article reviews
Tissue Microarray Device Minicore, supplied by Alphelys Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+microarray+device+minicore/tissue+arrayer+minicore/10__1097_slash_pai__0000000000001208-50-3-7
Average 90 stars, based on 1 article reviews
tissue microarray device minicore - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Microarray:Article Title: Expression and Clinical Significance of ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients Article Snippet: Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults.. Although studies regarding the association between the expression of Ki-67, CD10, BCL6, and MUM1 proteins, as well as c-MYC amplification and EBV status with clinicopathologic characteristics have rapidly progressed, their co-expression and prognostic role remain unsatisfactory.. Therefore, this study aimed to investigate the association between the expression of all markers and clinicopathologic features and their prognostic value in DLBCL. Blocking Assay:Article Title: Expression and Clinical Significance of ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients Article Snippet: Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults.. Although studies regarding the association between the expression of Ki-67, CD10, BCL6, and MUM1 proteins, as well as c-MYC amplification and EBV status with clinicopathologic characteristics have rapidly progressed, their co-expression and prognostic role remain unsatisfactory.. Therefore, this study aimed to investigate the association between the expression of all markers and clinicopathologic features and their prognostic value in DLBCL. |